

How can we build a more resilient U.S. pharmaceutical supply chain?

A more resilient supply chain can help reduce the frequency and duration of drug shortages in the U.S. At Fresenius Kabi, we're focused on creating resilience through these key areas.

MORE DEDICATION


Embracing Our Purpose

- More than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA's Essential Medicines List.¹
- We play a leading role in national coalitions to end drug shortages
- We are transparent and collaborative with customers and supply chain partners

MORE CAPACITY

Investing in a Robust U.S. Supply

- Fresenius Kabi has invested nearly \$1 billion in advanced U.S. manufacturing and logistics centers
- We delivered nearly 900 million units over the past two years²
- 74% of products for the U.S. are formulated, filled and packaged in the U.S.³



MORE AGILITY

Responding to Disruptions

- Fresenius Kabi is increasing safety stocks
- We shift production to speed up our response to market demands
- We cross-train employees on advanced manufacturing technologies

MORE REDUNDANCY

Diversifying Our Global Supply Chain

- Fresenius Kabi operates multiple FDA-approved sites in the U.S. and Europe
- We multisource components and raw materials
- We are approved to produce molecules at multiple sites

Read the full [article](#) and watch the [video](#) to learn how Fresenius Kabi is building resilience into America's pharmaceutical supply chain.



[MoreinAmerica.com](https://www.fresenius-kabi.com/MoreinAmerica.com)